Welcome to our dedicated page for Unicycive Therapeutics SEC filings (Ticker: UNCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Unicycive Therapeutics, Inc. (UNCY) SEC filings page on Stock Titan provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. Unicycive is a clinical-stage biotechnology company developing therapies for kidney diseases, and its filings offer structured insight into the progress of oxylanthanum carbonate (OLC) and UNI-494, as well as its capital markets activities and corporate governance.
Investors can review Form 8-K current reports where Unicycive discloses material events such as receipt of a Complete Response Letter for the OLC New Drug Application, updates from FDA Type A meetings, NDA resubmission timing, reverse stock split implementation, at-the-market equity offering amendments, preliminary financial information, and Nasdaq listing compliance. Certain 8-Ks also reference press releases on financial results, clinical data publications, and legal proceedings, including a purported securities class action related to public statements about the OLC NDA.
Annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) provide broader detail on Unicycive’s kidney disease pipeline, risk factors, research and development spending, general and administrative expenses, and descriptions of oxylanthanum carbonate and UNI-494, including orphan drug designation for prevention of delayed graft function in kidney transplant patients. These periodic filings also summarize the company’s status as an emerging growth company and its listing on the Nasdaq Capital Market under the symbol UNCY.
On Stock Titan, AI-powered tools can help interpret lengthy filings by highlighting key sections on regulatory milestones, capital structure changes such as reverse stock splits, at-the-market programs, and disclosed cash positions and runway commentary. Users can quickly locate discussions of OLC’s regulatory path, UNI-494 patents and designations, and updates that management reports through 8-Ks and other forms, enabling a more efficient review of Unicycive’s SEC reporting history.
Unicycive Therapeutics (NASDAQ: UNCY) has announced a 1-for-10 reverse stock split effective June 18, 2025, at 4:01 PM ET. The company's common stock began trading on a split-adjusted basis on the Nasdaq Capital Market on June 20, 2025, maintaining its "UNCY" symbol but with a new CUSIP number.
Key details of the reverse split:
- Reduced outstanding shares from 126,409,281 to approximately 12,768,239
- No fractional shares issued - fractional interests rounded up to the next whole share
- Proportionate adjustments made to stock options, warrants, and Series A-2 prime preferred stock conversion prices
- No change to authorized shares or par value
- No material change to stockholders' percentage ownership or voting power
The reverse split follows stockholder approval on June 9, 2025, which authorized the board to implement a split ratio between 1-for-2 and 1-for-20 before June 9, 2026. This corporate action affects multiple registration statements on Forms S-3 and S-8 currently on file with the SEC.